Our Pipeline
We are programming biology to create optimal therapeutics for the greatest impact on human health.
| Program | Lead Indication | Target | Generating | IND-enabling | Phase 1 | Collaborations | ||
|---|---|---|---|---|---|---|---|---|
| Immunology | ||||||||
| GB-0895 | Severe Asthma | TSLP |
|
|||||
| GB-7624 | Atopic Dermatitis | IL-13 |
|
|||||
| mAb | Ulcerative Colitis | TL1A |
|
|||||
| mAb | Atopic Dermatitis | OX40L |
|
|||||
| Mono and combo incl. bsAb |
Various | Various |
|
|||||
| Immuno-oncology | ||||||||
| Bispecific | NSCLC | Undisclosed |
|
The University of Texas
MD Anderson Cancer Center 50/50 |
||||
| Armored CAR-T | Advanced Solid Tumors | Undisclosed |
|
50/50
|
||||
| ADCs | ||||||||
| Protein Binder | ADC Toxin Neutralizer | Free MMAE |
|
|||||
| ADC | Advanced Solid Tumors | Undisclosed |
|
|||||
| Infectious Disease | ||||||||
| GB-0669 | Covid-19 PrEP | SARS-CoV-2 S2 |
|
|||||
| mAb | Covid-19 PrEP | SARS-CoV-2 RBD cl.IV |
|
|||||
| Undisclosed | ||||||||
| Amgen |
6 Undisclosed Programs
|
 |
||||||
| Novartis |
Multiple Undisclosed Programs
|
 |
||||||
Policy on Expanded Access (EA) to Investigational Drugs
Currently, participation in clinical trials is the only way for patients to gain access to Generate:Biomedicines’ investigational therapies. As more clinical data on the safety and efficacy of these investigational therapies become available, we will review and update our policy on Expanded Access.